Transaction price
Alnylam Pharmaceuticals·Products & Services·5 segments
Breakdown
| Segment | Q3 '23 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| License | — | — | — | — | — | $1.74B | $1.74B | $1.74B |
| Roche Development Services Obligation | $545.00M | $545.00M | $937.53M | $937.53M | $1.06B | — | $1.06B | $1.06B |
| Roche License Obligation | $310.00M | $310.00M | $375.00M | $375.00M | $675.00M | — | $675.00M | $675.00M |
| Research Services Obligation | $305.68M | $305.70M | — | — | $100.50M | $100.50M | $100.50M | $100.50M |
| Roche Technology Transfer Obligation | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | — | $2.00M | $2.00M |
| Total | — | — | — | — | — | $1.74B | $1.74B | $1.74B |
Segments
LicenseView metric
Research Services ObligationView metric
Roche Development Services ObligationView metric
Roche License ObligationView metric
Roche Technology Transfer ObligationView metric